| Hans-Günter Meyer-Thompson | Gabapentinoide
USA. FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression
USA. FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression
“With the evolution of the opioid crisis, getting ahead of new concerns or addressing those that are already evident requires examining signs of misuse and abuse as soon as any signal emerges.
Reports of gabapentinoid abuse alone, and with opioids, have emerged and there are serious consequences of this co-use, including respiratory depression and increased risk of opioid overdose death.“ (FDA - U. S. Food and Drug Administration, USA, 19.12.2019)
https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression